Form 4: CytomX CBO Granted 650,000 Stock Options

CytomX Therapeutics' Chief Business Officer, Rachael Lester, was granted 650,000 stock options with an exercise price of $3.74.

Summary

• Rachael Lester, Chief Business Officer of CytomX Therapeutics, Inc. (CTMX), was granted 650,000 stock options.
• The transaction date for this grant was October 20, 2025.
• The exercise price for these stock options is $3.74 per share.
• The options vest over four years: 25% on October 20, 2026 (one year anniversary of the Vesting Commencement Date), and then 1/48th of the shares will vest monthly thereafter.
• The options will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, which is October 20, 2029.
• The expiration date for these stock options is October 19, 2035.
• Following this transaction, Rachael Lester beneficially owns 650,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The filing reports a routine executive compensation event (stock option grant), which is generally neutral to slightly positive as it aligns management incentives with shareholder value. It does not contain information that would significantly alter the company's fundamental outlook.

Positives

• The grant of stock options aligns the Chief Business Officer's interests with those of shareholders, incentivizing long-term company performance.
• This compensation structure is a standard practice for executive retention and motivation.

Future Outlook

The filing indicates a future vesting schedule for the granted stock options, with 25% vesting on October 20, 2026, and monthly vesting thereafter, leading to full vesting by October 20, 2029, contingent on continued service.

Industry Context

The grant of stock options to a Chief Business Officer is a common form of executive compensation within the biotechnology and pharmaceutical industries, designed to attract, retain, and incentivize key talent by linking their financial interests to the company's long-term stock performance.

Comparison to Industry Standards

• The grant of stock options as part of executive compensation is a standard practice across the biotechnology and broader corporate landscape.
• Specific comparisons to the size or terms of similar grants at comparable companies (e.g., Amgen, Gilead Sciences, Regeneron Pharmaceuticals) would require detailed analysis of their respective compensation disclosures, which is not provided in this Form 4 filing.

Related Party Transactions

• The grant of 650,000 stock options to Rachael Lester, the Chief Business Officer, constitutes an executive compensation transaction between the company and a key officer.

Stakeholder Impact

• Shareholders: The grant aligns the Chief Business Officer's long-term financial interests with shareholder value creation.
• Employees: This reflects standard executive compensation practices, potentially influencing overall compensation philosophy.

Next Steps

• The stock options will begin vesting on October 20, 2026, with subsequent monthly vesting until fully vested on October 20, 2029.

Key Dates

Keywords

CytomX Therapeutics, CTMX, Stock Option, Executive Compensation, Insider Transaction, Form 4, Rachael Lester, Derivative Securities